Attached files

file filename
EX-99.1 - PRESS RELEASE DATED MARCH 13, 2012 - OMEROS CORPd314471dex991.htm

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2012

 

 

OMEROS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

 

Washington   001-34475   91-1663741
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

1420 Fifth Avenue, Suite 2600 Seattle, Washington 98101

(Address of principal executive offices, including zip code)

(206) 676-5000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On March 13, 2012, we issued a press release announcing the results of our Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit Number

  

Description

99.1    Press release dated March 13, 2012

 

-2-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OMEROS CORPORATION
By:   /s/ Gregory A. Demopulos, M.D.
  Gregory A. Demopulos, M.D.
  President, Chief Executive Officer and
Chairman of the Board of Directors

Date: March 13, 2012


EXHIBIT INDEX

 

Exhibit Number

  

Description

99.1    Press release dated March 13, 2012